# The Innate Central Nervous System Immune Response to an Experimental Immune Challenge in People With Fibromyalgia

> **NCT04263454** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 36 (actual)

## Conditions studied

- Fibromyalgia

## Interventions

- **DRUG:** Endotoxin, Escherichia Coli
- **PROCEDURE:** Magnetic Resonance Spectroscopy

## Key facts

- **NCT ID:** NCT04263454
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-11
- **Primary completion:** 2021-12-22
- **Final completion:** 2021-12-22
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04263454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04263454, "The Innate Central Nervous System Immune Response to an Experimental Immune Challenge in People With Fibromyalgia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04263454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*